MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that Durata Chief Executive Officer Paul R. Edick has been invited to deliver an overview of the company at the 11th Annual BIO Investor Forum. The Durata presentation will take place on Wednesday, October 10, 2012 at 1:30 p.m. PT in the Presidio Room of the Palace Hotel in San Francisco.
According to the Biotechnology Industry Organization (BIO), the annual, high-profile event connects biotech companies with leading investors to establish relationships, foster new partnerships and, ultimately, new medicines. Durata Therapeutics was invited to participate in the forum following a competitive screening process with input from BIO and the event’s advisory committee, which includes executives at top-tier firms focused on investing and banking in the life sciences industry.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.
Forward-looking statements
Any statements in this press release about Durata’s future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.